AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|
21.4 C
New York
Friday, July 24, 2026

Tag: HEA MTC PHA BIO

newssourceFORcompanyinformationcontent1releasesmarket

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China’s MAH Framework

CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel...

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on...

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and...

WuXi Biologics’ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety...

ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/SASKATOON, SK, June 17, 2026 /CNW/ - ZYUS Life Sciences Corporation...

Azitra, Inc. to Present at 2026 BIO International Convention

BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO...

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHEA MTC PHA BIO

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers